These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 36267045)

  • 1. Resistance of Lenvatinib in Hepatocellular Carcinoma.
    Guo J; Zhao J; Xu Q; Huang D
    Curr Cancer Drug Targets; 2022; 22(11):865-878. PubMed ID: 36267045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib: A Review in Hepatocellular Carcinoma.
    Al-Salama ZT; Syed YY; Scott LJ
    Drugs; 2019 Apr; 79(6):665-674. PubMed ID: 30993651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
    Shi T; Iwama H; Fujita K; Kobara H; Nishiyama N; Fujihara S; Goda Y; Yoneyama H; Morishita A; Tani J; Yamada M; Nakahara M; Takuma K; Masaki T
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma.
    Baxter MA; Glen H; Evans TR
    Future Oncol; 2018 Aug; 14(20):2021-2029. PubMed ID: 29783903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma.
    Fan FM; Fleishman JS; Chen J; Chen ZS; Dong HH
    Drug Discov Today; 2024 Aug; 29(8):104069. PubMed ID: 38936692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
    Oikonomopoulos G; Aravind P; Sarker D
    Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
    Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
    Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
    Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
    J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
    Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
    Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
    Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study.
    Chon YE; Kim DY; Kim MN; Kim BK; Kim SU; Park JY; Ahn SH; Ha Y; Lee JH; Lee KS; Kang B; Kim JS; Chon HJ; Kim DY
    Clin Mol Hepatol; 2024 Jul; 30(3):345-359. PubMed ID: 38468561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
    Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
    Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Mimura T; Minami A; Momose K; Hirano H; Tanaka M; Ueda Y; Tai K; Yasuhara Y; Nakagawa D; Yamamoto A; Kido M; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2024 Jul; 44(7):3097-3103. PubMed ID: 38925835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma].
    Watanabe T; Koyama N
    Nihon Yakurigaku Zasshi; 2019; 153(5):242-248. PubMed ID: 31092758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
    Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
    J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
    J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.